Patients with diabetic foot infection who were taking statins were less likely to undergo a major amputation than those who were not, according to a retrospective study from northern Jordan published in Frontiers in Endocrinology. The gap was widest among patients on high-intensity statin therapy.
Statins and amputation: the Irbid study
Jana Abdallah, Mera A. Ababneh, Anan S. Jarab, Abeer M. Ayoub, Wasan Khwaileh and Nada A. Alsaleh, from Jordan University of Science and Technology and Princess Nourah bint Abdulrahman University in Riyadh, reviewed the records of 376 adults admitted with diabetic foot infection to King Abdullah University Hospital in Irbid between January 2020 and April 2024. Of these, 262 were taking a statin (182 at moderate intensity and 79 at high intensity) and 114 were not.
Major amputation, defined as amputation through or above the ankle, occurred in 21.9% of patients not taking a statin, 12.6% of those on a moderate-intensity statin and 7.6% of those on a high-intensity statin. After adjustment for other factors, statin use was associated with lower odds of a more severe amputation, with an adjusted odds ratio of 0.43 for both intensity levels. Minor amputation rates, below the ankle, were similar: 36.0% without statins and 31.7% with them.
Statin use made no significant difference to length of hospital stay, with a median of 10 days for non-users and 9 days for users. In-hospital deaths were few in both groups.
Association, not proof
The authors are clear that their design “precludes causal inference”. This was a single-centre, retrospective study. Patients were not randomised, adherence to statins could not be checked, and how long patients had been taking them was not recorded. People prescribed statins may also differ from those who are not, for example in how regularly they see a doctor. The difference between moderate and high intensity was not statistically significant. The authors call for randomised controlled trials.
The findings are biologically plausible. Peripheral arterial disease is a major driver of amputation in diabetic foot disease, and statins are already recommended for most people with diabetes and for those with peripheral arterial disease to reduce cardiovascular risk.
IMEA POD Perspective
This study does not show that statins save limbs, but it gives foot teams in the region a practical prompt. Many patients who arrive with an infected diabetic foot are not on a statin even though guidelines already say they should be, for their hearts if nothing else. A medication review on admission costs little: check whether the patient is on a statin, at what intensity, and whether they are actually taking it, then work with the physician or endocrinologist to close the gap. Podiatrists in outpatient clinics can ask the same question at every high-risk foot review. It is also encouraging to see clinical research on diabetic foot outcomes coming from Jordan and Saudi Arabia. The next step should be multi-centre prospective data from across the Middle East, where diabetes rates and amputation burdens are among the highest in the world.
Sources and further reading
- Abdallah J, Ababneh MA, Jarab AS, Ayoub AM, Khwaileh W, Alsaleh NA. The impact of statin therapy on amputation risk in patients with diabetic foot infection: a retrospective cohort study from Jordan. Frontiers in Endocrinology, 2026
- IWGDF Guidelines on the prevention and management of diabetes-related foot disease
- IMEA POD: Gulf Diabetic Foot Working Group publishes first Gulf-specific DFU guidelines
